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After recreational exposure to river water in Uganda, 12 
(17%) of 69 persons had evidence of schistosome infection. 
Eighteen percent self-medicated with praziquantel prophy-
laxis immediately after exposure, which was not appropri-
ate. Travelers to schistosomiasis-endemic areas should 
consult a travel medicine physician.
S
chistosomiasis, a parasitic infection caused by schisto-
some  ﬂ   ukes, affects 207 million persons worldwide, 
mostly in sub-Saharan Africa (1). Schistosomiasis has been 
reported among travelers (2–12); 3 outbreaks have been re-
ported among white-water rafters on the Omo River in Ethio-
pia (2,7,10). During September–November 2007, the Centers 
for Disease Control and Prevention (CDC) received reports 
of schistosome infection among travelers returning from 
white-water rafting on the Nile River, Jinja District, Uganda. 
Approximately 12,000 persons raft each year in Uganda, and 
local rafting companies believe that exposure to fast-moving 
white water during rafting and kayaking presents a low risk 
for schistosomiasis (C. McLeay, pers. comm.).
The Study
During November 30–December 5, 2007, we enrolled 
a convenience sample of competitors and spectators attend-
ing the international Nile Freestyle Festival kayaking event 
and tourists on commercial rafting trips in Jinja District, 
Uganda. We administered a questionnaire to collect infor-
mation about participants’ demographic characteristics, 
use of praziquantel (the antiparasitic drug treatment for 
schistosome infection), and exposure to fresh water. Three 
months after enrollment, we asked study participants who 
had had a negative or indeterminate result from a blood 
test for schistosome antibodies at the time of enrollment to 
complete an Internet-based questionnaire about freshwater 
exposures, health symptoms, and medical tests or treat-
ments for schistosomiasis since enrollment.
We measured infection by collecting two 5-mL blood 
samples 3 months apart and testing them for evidence of 
schistosome antibody seroconversion. We tested for pres-
ence of schistosome-speciﬁ  c antibodies using an ELISA 
assay screening test that is 99% sensitive for Schistosoma 
mansoni and 90% sensitive for S. hematobium (10). We 
conﬁ   rmed FAST-ELISA–positive samples using an S. 
mansoni–speciﬁ   c immunoblot to detect species-speciﬁ  c 
antibody. We tested all samples using an S. hematobium–
speciﬁ  c immunoblot, which is 95% sensitive and 99% spe-
ciﬁ  c for each species (13). We deﬁ  ned a positive test result 
as positive results by both tests, an indeterminate result as 
positive by FAST-ELISA but negative by immunoblot, and 
a negative result as negative by both tests.
We deﬁ  ned study participant exposures from 2 weeks 
before enrollment until second sample collection by 4 activ-
ity categories: no water-contact activity, swimming/wading 
only, kayaking/rafting only, and swimming/wading plus 
kayaking/rafting. We deﬁ  ned schistosome antibody sero-
conversion in participants as either being ﬁ  rst-test–negative 
and second-test–positive, or being ﬁ  rst-test–negative and 
second-test–indeterminate. We compared characteristics 
between groups using the χ2 test for categorical data and 
the Mann-Whitney test for continuous variables (14). We 
expressed the risk for infection as the proportion of persons 
in each activity category who had evidence of schistosome 
antibody seroconversion and calculated the Mantel-Haen-
szel χ2 test for trend (14). We performed all analyses using 
SAS version 9.1 (SAS Institute, Cary, NC, USA). The CDC 
Institutional Review Board and the Uganda Virus Research 
Institute approved this study.
We enrolled 150 study participants; 2 subsequently 
withdrew. Thirty-ﬁ   ve (24%) participants were not fol-
lowed up because their ﬁ  rst blood test was positive; all of 
these persons reported previous exposure to fresh water in 
schistosomiasis-endemic countries. Of the remaining 113 
persons eligible for follow-up, 69 (61%) provided a second 
blood sample. Persons who provided only 1 blood sample 
were more likely to be younger (p = 0.005) and female (p 
= 0.03) (Table 1).
Of 69 persons followed up, 23% had fever, 13% 
cough, 10% skin rash, and 10% abdominal pain; 8% re-
ported prickling skin. None reported physician-diagnosed 
acute schistosomiasis. Twelve (17%) of the 69 persons 
with 2 blood samples had evidence of seroconversion. No 
DISPATCHES
866  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 5, May 2010
Author afﬁ  liations: Centers for Disease Control and Prevention, At-
lanta, Georgia, USA (O.W. Morgan, G. Brunette, B.K. Kapella, I. 
McAuliffe, W. Li, N. Marano, S.J. Olsen, W.E. Secor, J.W. Tappero, 
P.P. Wilkins, S.P. Montgomery); Ugandan Virus Research Institute, 
Entebbe, Uganda (E. Katongole-Mbidde); and Ministry of Health, 
Kampala, Uganda (S. Okware)
DOI: 10.3201/eid1605.091740Schistosomiasis, Upper Nile River
seroconversions were identiﬁ  ed among the 9 persons who 
reported no water-contact activities. Serologic data sug-
gested that infection occurred in 1 (13%) of 8 reporting 
swimming/wading only; 4 (15%) of 26, kayaking/rafting 
only; and 7 (27%) of 26, swimming/wading plus kayaking/
rafting (Table 2).
Of 106 persons for whom data were recorded, 19 
(18%) reported self-medicating with praziquantel while 
at the kayaking competition. Of the 12 participants with 
evidence of seroconversion, 6 had data recorded about self-
medication, none of whom took praziquantel.
Conclusions
Approximately one ﬁ  fth of persons with recreational 
exposure to water on the upper Nile River in Jinja District 
showed evidence of schistosome antibody seroconversion. 
Infection occurred among persons who reported swim-
ming/wading only, kayaking/rafting only, and both activi-
ties, which refutes the belief that exposure to fast-moving 
water presents a low risk for schistosomiasis.
Exposure to schistosomes is likely to be highest in 
slow-moving water near riverbanks; thus, persons who go 
rafting may be at highest risk while putting their kayaks/
rafts into and taking them out of the river. Although we 
were unable to estimate the risk for infection attributable to 
fast-moving white-water exposure alone, we did ﬁ  nd that 
persons who reported swimming/wading and kayaking/
rafting had the highest risk, possibly because of increased 
duration of exposure (4).
Eighteen percent of study participants reported self-
medicating with praziquantel immediately or shortly after 
river water exposure. However, they would not have been 
protected against schistosomiasis because praziquantel acts 
against mature schistosome parasites and thus is most ef-
fective if taken after the parasite has developed to the adult 
stage, which is 4–6 weeks after infection. Local advice 
about using praziquantel to prevent schistosomiasis may 
not be appropriate; because indigenous populations have 
ongoing exposure, timing of treatment is not as critical. 
Travelers with discrete freshwater exposures in schistoso-
miasis-endemic countries should consult a travel medicine 
physician. In addition, information could be made available 
to pharmacies, rafting companies, and travelers about when 
to take praziquantel.
Our study had several limitations. The study cohort 
was a convenience sample, and participants might not have 
had equal chance of being enrolled. Use of this sample 
may have introduced bias, although whether any such bias 
would contribute to overestimation or underestimation of 
risk is unclear. Because schistosome antibody tests do not 
differentiate newly acquired infection, we excluded per-
sons with ﬁ  rst-test–positive results from the study follow-
up. However, if these persons were more likely to have had 
a higher risk for infection, excluding them would have led 
us to underestimation risk for infection.
More than 12,000 persons take rafting trips in Uganda 
each year. Many travelers do not follow advice to avoid 
freshwater activities in schistosomiasis-endemic countries 
(15). Travelers should be made aware that white-water ex-
posure presents a risk for schistosomiasis and that treat-
ment with praziquantel should be at least 4–6 weeks after 
last exposure, preferably under the direction of a travel 
medicine physician.
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Table 1. Characteristics of 113 recreational users of the upper Nile River who participated in a study to determine risk for schistosome
infection, were eligible for study follow-up, and provided 1 or 2 blood samples, Uganda, 2007* 
Characteristic
Provided 1 blood sample,  
no. (%), n = 44 
Provided 2 blood samples, 
no. (%), n = 69  p value† 
Male sex  14 (32)  34 (50)  0.03
Main reason for being at the Nile 
  Rafter  20 (45)  32 (46)  0.4
  Spectator at the competition  12 (27)  18 (26) 
  Kayak competitor  9 (21)  8 (12) 
  Other  3 (7)  11 (16) 
Region of residence 
  Africa  6 (14)  16 (23)  0.6
  Americas  12 (27)  16 (23) 
  Europe  15 (34)  17 (25) 
  Australasia  7 (16)  12 (17) 
  None given  4 (9)  8 (12) 
*Median ages (ranges) of study participants were as follows: 1 blood sample provided: 25 y (18–41 y); 2 blood samples provided, 29 y (16–67 y); p = 
0.005. 
†p values estimated by using the Mann-Whitney test for age and a Ȥ
2 test for all other variables. 
Table 2. Proportion of recreational users of the upper Nile River 
who had schistosome infection, Uganda, 2007* 
Activity  No. infected/total (%) 
No water-contact activity  0/9
Swimming/wading only  1/8 (13) 
Kayaking/rafting only  4/26 (15) 
Kayaking/rafting and swimming/wading  7/26 (27) 
All study participants  12/69 (17) 
*Activity categories are mutually exclusive. Ȥ
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